Could a simpler surgery be safer for aggressive uterine cancer?
NCT ID NCT06900582
First seen Feb 20, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This study compares two surgical approaches for women with early-stage, high-risk endometrial cancer that has a p53 gene mutation. One group will get the standard extensive lymph node removal, while the other gets a less invasive sentinel node biopsy. The goal is to see if the simpler procedure is just as good at preventing cancer from coming back, with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sentinel lymph node mapping (a less invasive surgical procedure to check for cancer spread)
What this could lead to
If successful, this could show that a less invasive surgery is safe for women with this aggressive type of endometrial cancer, reducing side effects like lymphedema.
What could go wrong
This is a relatively early-stage trial (Phase NA) with 374 participants. The less invasive approach might not catch all cancer spread, potentially leading to higher recurrence rates.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.